Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Respir Res. 2018 Jul 27;19(1):139. doi: 10.1186/s12931-018-0847-3.
Probiotics could prevent Pseudomonas aeruginosa colonization in lower respiratory tract (LRT) and reduced P. aeruginosa ventilator-associated pneumonia (VAP) rate. Recent studies also suggested that probiotics could improve lung inflammation in mice infected with P. aeruginosa. It seems that microbiota regulation may be a potential therapy for P. aeruginosa VAP patients. However, we know less about the LRT microbial composition and its correlation with prognosis in P. aeruginosa VAP patients. This study aimed to characterize LRT microbiota in P. aeruginosa VAP patients and explore the relationship between microbiota and patient prognosis.
Deep endotracheal secretions were sampled from subjects via intubation. Communities were identified by 16S ribosomal RNA gene sequencing. The relationship between microbiota and the prognosis of P. aeruginosa VAP patients were evaluated. Clinical pulmonary infection score and the survival of intensive care unit were both the indicators of patient prognosis.
In this study, the LRT microbial composition of P. aeruginosa VAP patients was significantly different from non-infected intubation patients, and showed significant individual differences, forming two clusters. According to the predominant phylum of each cluster, these two clusters were named Pro cluster and Fir-Bac cluster respectively. Patients from Pro cluster were dominated by Proteobacteria (adj.P < 0.001), while those from Fir-Bac cluster were dominated by Firmicutes, and Bacteroidetes (both adj.P < 0.001). These two varied clusters (Pro and Fir-Bac cluster) were associated with the patients' primary disease (χ-test, P < 0.0001). The primary disease of the Pro cluster mainly included gastrointestinal disease (63%), and the Fir-Bac cluster was predominantly respiratory disease (89%). During the two-week dynamic observation period, despite the use of antibiotics, the dominant genera and Shannon diversity of the LRT microbiota did not change significantly in patients with P. aeruginosa VAP. In prognostic analysis, we found a significant negative correlation between Lactobacillus and clinical pulmonary infection score on the day of diagnosis (P = 0.014); but we found no significant difference of microbial composition between survivors and non-survivors.
LRT microbial composition was diversified among P. aeruginosa VAP patients, forming two clusters which were associated with the primary diseases of the patients.
益生菌可预防铜绿假单胞菌在下呼吸道(LRT)定植,并降低铜绿假单胞菌呼吸机相关性肺炎(VAP)的发生率。最近的研究还表明,益生菌可改善铜绿假单胞菌感染小鼠的肺部炎症。似乎微生物群调节可能是铜绿假单胞菌 VAP 患者的一种潜在治疗方法。但是,我们对铜绿假单胞菌 VAP 患者的 LRT 微生物组成及其与预后的关系了解较少。本研究旨在描述铜绿假单胞菌 VAP 患者的 LRT 微生物组,并探讨微生物组与患者预后的关系。
通过插管从受试者中采集深部气管分泌物。通过 16S 核糖体 RNA 基因测序鉴定群落。评估微生物组与铜绿假单胞菌 VAP 患者预后的关系。临床肺部感染评分和重症监护病房的生存率均为患者预后的指标。
在这项研究中,铜绿假单胞菌 VAP 患者的 LRT 微生物组成明显不同于未感染插管患者,且表现出明显的个体差异,形成两个聚类。根据每个聚类的主要门,将这两个聚类分别命名为 Pro 聚类和 Fir-Bac 聚类。Pro 聚类中的患者主要以变形菌门为主(adj.P<0.001),而 Fir-Bac 聚类中的患者则以厚壁菌门和拟杆菌门为主(均 adj.P<0.001)。这两个不同的聚类(Pro 和 Fir-Bac 聚类)与患者的主要疾病有关(χ检验,P<0.0001)。Pro 聚类的主要疾病主要包括胃肠道疾病(63%),而 Fir-Bac 聚类主要为呼吸系统疾病(89%)。在两周的动态观察期间,尽管使用了抗生素,但铜绿假单胞菌 VAP 患者的 LRT 微生物群的优势属和 Shannon 多样性并未发生明显变化。在预后分析中,我们发现诊断当天乳酸杆菌与临床肺部感染评分呈显著负相关(P=0.014);但我们没有发现存活者和非存活者之间的微生物组成有显著差异。
铜绿假单胞菌 VAP 患者的 LRT 微生物组成多样化,形成两个与患者主要疾病相关的聚类。